Edivoxetine

Edivoxetine

Substrates of Human CYP2D6

Published in Shufeng Zhou, Cytochrome P450 2D6, 2018

Edivoxetine hydrochloride (LY2216684) is a highly selective and potent norepinephrine reuptake inhibitor under clinical development for the treatment of attention-deficit/hyperactivity disorder and depression (Jin et al. 2013; Kielbasa et al. 2015; Lin et al. 2014; Markowitz and Brinda 2014). In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped because of lack of efficacy compared to SSRI alone in three separate clinical trials. Edivoxetine is readily absorbed and metabolized by CYP2D6 and 3A4 (Kielbasa et al. 2012). The Tmax is approximately 2 h postdose, and the plasma t1/2 is approximately 4–6 h irrespective of the dose. Pharmacokinetic parameters are not substantially different between children and adults. Edivoxetine may be a promising nonstimulant therapeutic agent.

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

View Article

Journal Information

Published in Expert Opinion on Emerging Drugs, 2020

Marco Pozzi, Silvana Bertella, Erika Gatti, Gabriëlla G. A. M. Peeters, Carla Carnovale, Stefania Zambrano, Maria Nobile

Also, the NRI edivoxetine showed quite good efficacy, but the safety profile was similar to that of atomoxetine (including nausea vomiting and somnolence), even though better than methylphenidate (including sleep disorder, reduced appetite-weight loss).

Explore chapters and articles related to this topic

Substrates of Human CYP2D6

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)